▶ ORFORGLIPRON · SUBTOPIC · DOSING LITERATURE

ORFORGLIPRON Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of ORFORGLIPRON. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for ORFORGLIPRON reports the following route(s) of administration: Oral (Phase 3 clinical). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of ORFORGLIPRON.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for ORFORGLIPRON of approximately ~24-30 hours (once-daily oral). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of ORFORGLIPRON. Refer to the original publication for full protocol detail.

Wharton S, et al. (2023) reports the ORFORGLIPRON protocol used in Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity, published in N Engl J Med. PMID 37364188. See the source for the protocol-level dose range, frequency, and duration. link
Frias JP, et al. (2023) reports the ORFORGLIPRON protocol used in Efficacy and safety of an orally administered GLP-1 receptor agonist (orforglipron) in adults with type 2 diabetes, published in N Engl J Med. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What is orforglipron?

Orforglipron (LY3502970) is an orally bioavailable non-peptide small-molecule allosteric agonist of the GLP-1 receptor developed by Eli Lilly. It is the first oral GLP-1 candidate that does not require the specialized absorption formulation used by oral GLP-3.

▶ How is orforglipron different from GLP-3?

Orforglipron is a small molecule taken orally without dietary restriction. GLP-3 is a peptide that requires subcutaneous injection or a specialized oral formulation taken on an empty stomach with limited water and at least 30 minutes before eating.

▶ Daily dose in trials?

Phase 2 used daily oral doses of 12 mg to 45 mg. This wiki does not recommend any human dose.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · n/a · tablet formulation

Reconstituted · n/a

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Investigational. Phase 3 ACHIEVE/ATTAIN programs ongoing.

WADA · Not currently listed on the WADA Prohibited List.

◀ ORFORGLIPRON OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19